National Institute on Drug Abuse

The National Institute on Drug Abuse is presented in Dopesick as an important source of evidence about opioid addiction and its treatment, most visibly through director Nora Volkow’s defense of long-term medication-assisted treatment. Its role in the narrative is not simply to endorse a clinical approach: the institute’s findings stand against short-term detoxification, while patients encounter treatment systems shaped by limited access, abstinence-oriented programs, and disputes over whether medication counts as recovery.

Institutional Voice and the Treatment Question

The book identifies the National Institute on Drug Abuse (NIDA) through the authority of its director, Nora Volkow, and through the treatment evidence she invokes. In an interview discussed in connection with Jesse Bolstridge’s care, Volkow emphasized that evidence supports long-term maintenance with medication when it is combined with behavioral treatment and recovery support, rather than short detoxification programs designed to produce abstinence. The distinction is consequential: medication is not framed as a brief aid to get through withdrawal, but as continuing treatment for opioid-use disorder.

The institute’s position is also situated within a wider consensus. Dopesick says that NIDA, the Institute of Medicine, the World Health Organization, and the White House drug czar’s office agreed that indefinite, and perhaps lifelong, maintenance treatment was superior to abstinence-based rehabilitation for opioid-use disorder. The book does not depict this consensus as a guarantee that patients could obtain such care. Instead, it sets the scientific case beside treatment practices that often remained organized around abstinence.

Jesse’s experience makes that gap concrete. His earlier rehabilitation in Jacksonville included intensive counseling and medical detox, and he briefly received buprenorphine, more commonly known by the brand name Suboxone. He was tapered off the medication after three weeks, a practice the book describes as common and increasingly controversial. The program’s abstinence aim thus diverged from the long-term maintenance approach that Volkow said the evidence supported. This contrast is not presented as a dispute over terminology alone: it concerns how long treatment continues and whether a patient retains medication that can reduce cravings and help prevent withdrawal.

Evidence Against Short-Term Detoxification

The National Institute on Drug Abuse’s treatment position recurs in the book’s account of the risks of discontinuing medication. Volkow explained that when patients are weaned too soon, a subsequent relapse can be misread as proof that medication-assisted treatment is ineffective. That interpretation, she argued, reinforces faulty assumptions about the treatment. The cycle matters: a treatment course ends, a patient returns to illicit opioids, and the resulting relapse may be used to discredit the very care that was withdrawn.

Dopesick places this warning alongside research and clinical experience about what happens after tapering. One study cited in the book found that half of users relapsed within a month of being weaned from buprenorphine; the lower the dose at the time of tapering, the better the outcome. A separate five-year study found that after eighteen months, roughly one-third of buprenorphine patients were drug-free, one-third remained on medication-assisted treatment, and most of the remainder had returned to heroin or illicit opioids. These findings help explain why continued treatment, rather than a short course ending in medication withdrawal, became central to the argument represented by Volkow.

Volkow also addressed people who bought Suboxone on the black market. The book reports her view that many were trying to avoid opioid withdrawal, and that this was safer for them than returning to heroin. That framing distinguishes unsafe or illicit access from the function the medication may serve: avoiding withdrawal and reducing exposure to a more dangerous alternative. It also challenges a simple assumption that non-prescribed use means a person is seeking intoxication rather than trying to manage dependence.

Guidance Meets Unequal Access

The book’s examples show how far a treatment recommendation could be from treatment in practice. Jesse’s earlier rehabilitation cost $25,000, which he still owed despite being covered by his mother’s insurance and making weekly payments from his checking account. Kristi Fernandez could not afford to send him immediately to another rehabilitation program or accompany him to ensure that a transfer worked. The institute’s case for continuing medication therefore appears within a family’s financial and logistical constraints, not outside them.

Tess Henry’s care reveals a different set of barriers. During pregnancy, she entered the Life Center of Galax, one of the few Virginia facilities described as accepting patients on medication-assisted treatment. She took Subutex, a buprenorphine formulation then recommended for some pregnant patients. Later, buprenorphine helped her feel normal and prevented withdrawal while reducing cravings, but access to her addiction doctor required a substantial cash payment up front and repeated cash-only follow-up visits. Insurance covered most of the medication’s cost, yet the clinical visits needed to receive and monitor it remained a separate obstacle.

At the time described, federal rules limited medication-assisted-treatment-certified doctors to 100 patients, a cap later increased to 275 in response to the opioid crisis. The book notes that treatment access in Virginia broadened in 2017, but that the need for care was recognized slowly and services reached many communities even more slowly. These details qualify the significance of NIDA’s evidence: knowing which treatment performs better does not itself remove limits on the number of patients clinicians may treat, the cost of appointments, or local shortages of providers.

Scientific Evidence in a Contested Policy Climate

The institute also appears within debate over whether medication-assisted treatment belongs in recovery programs and public policy. At a 2014 NIDA meeting, harm-reduction activist and historian Caroline Jean Acker was scolded for advocating needle exchange and naloxone distribution after a speaker separated people who became medically addicted from illicit users. Acker described the distinction as if there were no movement between those categories. Her account places the meeting within a wider political caution about appearing permissive toward drugs; she also said federal employees at the Substance Abuse and Mental Health Services Administration had been told not to use the term harm reduction. The episode does not establish a single institutional position on every harm-reduction measure, but it shows how arguments about categories and public acceptability surrounded the agency’s field of work.

Volkow’s evidence carried into a later federal policy encounter. After the 21st Century Cures Act appropriated money for treatment and prevention, Health and Human Services Secretary Tom Price publicly described medication-assisted treatment as substituting one opioid for another, disappointing treatment advocates. A Tennessee public health official told the author that Volkow changed Price’s stance after showing him the scientific facts. Price later resigned amid a scandal over taxpayer-funded charter flights, and his successor, Alex M. Azar II, signaled an intention to expand access to medication-assisted treatment. The sequence illustrates the contested path from research evidence to official policy: evidence could inform senior officials, but public statements and commitments shifted over time.

Narrative Significance

The National Institute on Drug Abuse gives Dopesick a counterweight to the treatment systems the book describes. Its evidence makes the consequences of brief medication courses, premature tapering, and medication stigma legible as more than individual failures of will. At the same time, the narrative does not treat scientific agreement as a solution in itself. Patients still confronted cost, limited provider capacity, waiting lists, abstinence-oriented rehabilitation, and social settings where taking buprenorphine could be regarded as not being clean.

That tension is clearest where the institute’s treatment evidence meets a patient’s circumstances: Jesse was tapered after three weeks, while Tess encountered a costly and fragmented route to continuing care. Through Volkow’s interventions, the National Institute on Drug Abuse supplies a sustained argument for maintenance treatment; through the families’ experiences, the book shows why that argument could remain difficult to put into practice. The organization’s significance lies in this distance between evidence and delivery, and in the recurring struggle to make treatment policy answer to the needs of people living through addiction.